Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression

Key Points • KLF2 is downregulated by augmented JAK-STAT signaling in PV and ET, leading to upregulated thrombotic gene expression.• KLF2 transcript levels in PV and ET are inversely correlated with neutrophil and platelet counts but not hemoglobin and hematocrit.

[1]  R. Pawlinski,et al.  Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients , 2021, American journal of hematology.

[2]  J. Prchal,et al.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. , 2020, Blood advances.

[3]  S. Bojesen,et al.  Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the Copenhagen General Population Study , 2019, Journal of thrombosis and haemostasis : JTH.

[4]  G. Barosi,et al.  Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity , 2019, PloS one.

[5]  U. Sack,et al.  Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation , 2019, Front. Immunol..

[6]  T. Barbui,et al.  JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis , 2018, Blood Cancer Journal.

[7]  H. Hasselbalch,et al.  Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms , 2018, Blood.

[8]  O. Baser,et al.  Elevated White Blood Cell Levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data , 2018, Blood.

[9]  A. Schmaier,et al.  Neutrophil KLF2 Regulates Arterial and Venous Thrombosis , 2018, Blood.

[10]  C. Schooling,et al.  Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms , 2018, Annals of Internal Medicine.

[11]  M. Salama,et al.  Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses , 2018, Leukemia.

[12]  T. Barbui,et al.  Polycythemia vera treatment algorithm 2018 , 2018, Blood Cancer Journal.

[13]  H. Jo,et al.  KLF2 and KLF4 control endothelial identity and vascular integrity. , 2017, JCI insight.

[14]  J. Prchal,et al.  HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis , 2015, Journal of Molecular Medicine.

[15]  T. Mayadas,et al.  The multifaceted functions of neutrophils. , 2014, Annual review of pathology.

[16]  R. Mesa.  Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. , 2010, IDrugs : the investigational drugs journal.

[17]  S. Swamynathan.  Krüppel-like factors: Three fingers in control , 2010, Human Genomics.

[18]  P. Ziakas.  Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain , 2008, Haematologica.

[19]  P. Majumder,et al.  Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Mukesh K. Jain,et al.  Tumor Necrosis Factor Alpha-Mediated Reduction of KLF2 Is Due to Inhibition of MEF2 by NF-κB and Histone Deacetylases , 2005, Molecular and Cellular Biology.

[21]  D. Blickstein,et al.  Thrombotic complications in essential thrombocythemia with relatively low platelet counts , 1997, American journal of hematology.

[22]  J. Jelinek,et al.  Polycythemia vera is not initiated by JAK2V617F mutation. , 2007, Experimental hematology.